Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
The Korean Journal of Internal Medicine
;
: 259-262, 2002.
Artículo
en Inglés
| WPRIM
| ID: wpr-20178
ABSTRACT
BACKGROUND:
Advanced, unresectable pancreatic cancer is an extremely aggressive disease. The 5-year survival rate for pancreatic cancer is only less than 5%. Current therapeutic options for patients with locally advanced or metastatic disease are limited. This analysis is a retrospective evaluation of the efficacy and toxicity of gemcitabine regimen as first-line chemotherapy in patients with advanced pancreatic cancer.METHODS:
Seventeen chemotherapy-na ve patients with advanced or recurred pancreatic cancer were consecutively treated. Gemcitabine was diluted in normal saline and administered intravenously over 1 hour. Gemcitabine 1,000 mg/m2 was administered once weekly for 3 out of every 4 weeks.RESULTS:
The median age of patients was 55 years (range 44~82 years). Based on RECIST criteria, there were 5 cases of stable disease (45%) and 6 cases of progressive disease (55%) among the 11 assessable patients. The median survival time was 189 days (range, 84 to 409 days), the 1 year survival rate was 18% in all 17 patients. Grade 3~4 toxic side effect was leucopenia only (29%) and was easily managed without infection.CONCLUSION:
Gemcitabine is well tolerated, but has no objective response in advanced pancreatic cancer.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias Pancreáticas
/
Ribonucleótido Reductasas
/
Tasa de Supervivencia
/
Estudios Retrospectivos
/
Desoxicitidina
/
Antimetabolitos Antineoplásicos
Tipo de estudio:
Estudio observacional
Límite:
Adulto
/
Anciano
/
Aged80
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
The Korean Journal of Internal Medicine
Año:
2002
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS